Turning Point Therapeutics (NASDAQ:TPTX) CFO Acquires $99,990.00 in Stock

Turning Point Therapeutics (NASDAQ:TPTX) CFO Yi Larson purchased 2,222 shares of the stock in a transaction dated Tuesday, September 10th. The shares were bought at an average price of $45.00 per share, for a total transaction of $99,990.00.

NASDAQ:TPTX traded up $0.50 during trading hours on Thursday, reaching $45.51. The company’s stock had a trading volume of 11,692 shares, compared to its average volume of 203,889. Turning Point Therapeutics has a one year low of $24.21 and a one year high of $58.56. The business has a 50-day moving average of $45.11. The company has a current ratio of 32.35, a quick ratio of 32.35 and a debt-to-equity ratio of 0.01.

Turning Point Therapeutics (NASDAQ:TPTX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.05). On average, sell-side analysts forecast that Turning Point Therapeutics will post -2.88 earnings per share for the current fiscal year.



Several research firms have recently commented on TPTX. Wedbush began coverage on shares of Turning Point Therapeutics in a report on Monday. They set an “outperform” rating and a $63.00 price target on the stock. Wells Fargo & Co boosted their price target on shares of Turning Point Therapeutics from $53.00 to $62.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. Canaccord Genuity boosted their price target on shares of Turning Point Therapeutics from $53.00 to $56.00 and gave the company a “buy” rating in a report on Thursday, September 5th. Guggenheim began coverage on shares of Turning Point Therapeutics in a report on Wednesday, July 24th. They set a “buy” rating and a $58.00 price target on the stock. Finally, Zacks Investment Research restated a “hold” rating on shares of Turning Point Therapeutics in a report on Saturday, September 7th. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $52.63.

A number of large investors have recently modified their holdings of TPTX. Tower Research Capital LLC TRC bought a new stake in Turning Point Therapeutics in the second quarter worth $25,000. JPMorgan Chase & Co. bought a new stake in Turning Point Therapeutics in the second quarter worth $71,000. Wells Fargo & Company MN bought a new stake in Turning Point Therapeutics in the second quarter worth $72,000. Cubist Systematic Strategies LLC bought a new stake in Turning Point Therapeutics in the second quarter worth $90,000. Finally, Alpine Woods Capital Investors LLC bought a new stake in Turning Point Therapeutics in the second quarter worth $204,000. Hedge funds and other institutional investors own 58.17% of the company’s stock.

About Turning Point Therapeutics

Turning Point Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients.

Read More: How does a margin account work?

Receive News & Ratings for Turning Point Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turning Point Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.